The estimated Net Worth of Roberto Cuca is at least $1.47 Millón dollars as of 14 November 2023. Mr. Cuca owns over 10,000 units of Orasure Technologies stock worth over $265,077 and over the last 11 years he sold OSUR stock worth over $0. In addition, he makes $1,201,700 as Chief Financial Officer at Orasure Technologies.
Sign up
Mr. Cuca OSUR stock SEC Form 4 insiders trading
Roberto has made over 6 trades of the Orasure Technologies stock since 2014, according to the Form 4 filled with the SEC. Most recently he bought 10,000 units of OSUR stock worth $44,900 on 14 November 2023.
The largest trade he's ever made was buying 25,000 units of Orasure Technologies stock on 10 December 2014 worth over $100,000. On average, Roberto trades about 2,800 units every 142 days since 2014. As of 14 November 2023 he still owns at least 62,371 units of Orasure Technologies stock.
You can see the complete history of Mr. Cuca stock trades at the bottom of the page.
Wallmine is a radically better financial terminal.
Sign up in seconds, it's free!
Wallmine is a radically better financial terminal.
Sign up in seconds, it's free!
Roberto Cuca biography
Roberto E. Cuca J.D. serves as Chief Financial Officer of the Company. Mr. Cuca joined the Company in May 2018, initially serving as Senior Advisor until his appointment as the Company’s Chief Financial Officer in June 2018. Prior to joining the Company, Mr. Cuca served as Senior Vice President and Chief Financial Officer of Trevena, Inc., a clinical stage biopharmaceutical company, where he led the finance and investor relations functions and worked with senior management to establish and execute overall corporate strategy. Prior to his tenure with Trevana, Mr. Cuca held various leadership positions in the finance organization of Endo Health Solutions Inc., a pharmaceutical company, including Treasurer and Senior Vice President, Finance, where he was responsible for capital raises and cash management, mergers, acquisitions and licensing transactions, tax planning and compliance, and risk management. Before he joined Endo, Mr. Cuca served as the Director, Corporate and Business Development at moksha8 Pharmaceuticals, Inc., an emerging markets-focused pharmaceutical company, and as an equity analyst covering U.S. pharmaceutical companies at J.P. Morgan Chase & Co. Mr. Cuca received an M.B.A. from The Wharton School of the University of Pennsylvania, a Juris Doctor from Cornell Law School, and an A.B. from Princeton University. Mr. Cuca is also a CFA Charterholder.
What is the salary of Roberto Cuca?
As the Chief Financial Officer of Orasure Technologies, the total compensation of Roberto Cuca at Orasure Technologies is $1,201,700. There are 2 executives at Orasure Technologies getting paid more, with Stephen Tang having the highest compensation of $2,114,820.
How old is Roberto Cuca?
Roberto Cuca is 52, he's been the Chief Financial Officer of Orasure Technologies since 2018. There are 12 older and 5 younger executives at Orasure Technologies. The oldest executive at Orasure Technologies Inc. is Ronny Lancaster, 68, who is the Independent Director.
What's Roberto Cuca's mailing address?
Roberto's mailing address filed with the SEC is C/O TELA BIO, INC., 1 GREAT VALLEY PARKWAY, SUITE 24, MALVERN, PA, 19355.
Insiders trading at Orasure Technologies
Over the last 21 years, insiders at Orasure Technologies have traded over $21,897,384 worth of Orasure Technologies stock and bought 196,200 units worth $1,037,188 . The most active insiders traders include Douglas A Michels, Ronald H Spair y Michael J Gausling. On average, Orasure Technologies executives and independent directors trade stock every 43 days with the average trade being worth of $221,123. The most recent stock trade was executed by Kathleen Gallagher Weber on 19 December 2023, trading 24,129 units of OSUR stock currently worth $194,238.
What does Orasure Technologies do?
based in bethlehem, pennsylvania, orasure technologies is a leader in the development, manufacture and distribution of oral fluid diagnostic and collection devices and other technologies designed to detect or diagnose critical medical conditions. these products include tests for the detection of antibodies to the hiv virus, including the oraquick® in-home hiv test, oraquick advance® rapid hiv-1/2 antibody test and the orasure® hiv-1 oral specimen collection device, a test for antibodies to the hcv virus, the oraquick® hcv rapid antibody test, and oral fluid testing solutions for drugs of abuse testing, including intercept® oral fluid drug testing system and q.e.d.® saliva alcohol test. orasure also manufactures and sells several leading cryosurgical products. these include: histofreezer®, a product for the cryosurgical removal of common and plantar warts and several other benign skin lesions, sold to the professional or physician office market, as well as an over-the-counter product fo
What does Orasure Technologies's logo look like?
Complete history of Mr. Cuca stock trades at Orasure Technologies, Trevena Inc y TELA Bio
Orasure Technologies executives and stock owners
Orasure Technologies executives and other stock owners filed with the SEC include:
-
Stephen Tang,
President, Chief Executive Officer, Director -
Dr. Stephen S. Tang,
Pres, CEO & Director -
Roberto Cuca,
Chief Financial Officer -
Kathleen Gallagher Weber,
Exec. VP & Bus. Unit Leader of Molecular Solutions -
Jack Jerrett,
Senior Vice President, Chief Compliance Officer, General Counsel, Secretary -
Kathleen Weber,
Executive Vice President, Business Unit Leader, Molecular Solutions at DNAG -
Scott Gleason,
Sr. VP of Investor Relations & Corp. Communications and Interim CFO -
Michael Celano,
Independent Chairman of the Board -
Ronny Lancaster,
Independent Director -
Eamonn Hobbs,
Independent Director -
Mara Aspinall,
Independent Director -
James Datin,
Independent Director -
David Shulkin,
Independent Director -
Lelio Marmora,
Director -
Michele Miller,
Vice President - Finance, Controller, Assistant Secretary -
Lisa Nibauer,
Executive Vice President, Business Unit Leader, Infectious Disease -
Amy Steigerwalt,
VP of HR -
David A. Rappaport C.F.A., CFA,
Sr. VP Corp. Devel., Strategy & Integration -
Carrie Eglinton Manner,
Pres, CEO & Director -
Michele Marie Miller,
VP of Fin., Controller & Assistant Sec. -
Agnieszka M. Gallagher J.D.,
Gen. Counsel, Chief Compliance Officer & Sec. -
Lisa Nibauer,
Pres of Diagnostics -
Jeanne Mell,
VP of Corp. Communications -
Michele Marie Anthony,
SVP Finance & CAO -
Douglas G Watson,
Director -
Mark L Kuna,
VP & Controller -
Roger L Pringle,
Director -
Michael Reed,
SVP R&D and CSO -
Ronald H Spair,
Exec. VP & CFO -
Douglas A Michels,
President and CEO -
Brian Smith,
EVP & BU Lead - Molecular -
Nancy J Gagliano,
Director -
Gregory B Lawless,
Director -
Aradhana Sarin,
Director -
Gerald M Ostrov,
Director -
Eric Whitters,
SVP, Research and Development -
Stephen R Lee,
EVP & Chief Science Officer -
P Michael Formica,
Exec. VP - Operations -
Michael J Gausling,
President & CEO -
Joseph E Zack,
Exec. VP, Marketing & Sales -
Manuel O. Mendez,
VP, Marketing and Sales -
Frank G Hausmann,
Director -
Jack Goldstein,
Director -
Carter H Eckert,
Director -
Ii Anthony Zezzo,
EVP & BU Lead - Infectious -
Charles W Patrick,
Director -
John P. Kenny,
Director -
Robert W. Mc Mahon,
Director -
Agnieszka Gallagher,
General Counsel & CCO -
Scott Gleason,
Interim CFO/SVP IR -
Anne Clem Whitaker,
Director -
Manner Carrie Eglinton,
President & CEO -
Kenneth J Mc Grath,
Chief Financial Officer